---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013047"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:31:20.426956+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Voyager Q2 net loss $22.2M, launches anti-Aβ gene therapy for Alzheimer's

## Summary
- Q2 2023 collaboration revenue $4.9M (up from $0.7M YoY); net loss $22.2M vs $19.1M YoY.
- Cash, equivalents and marketable securities $272.7M as of June 30, 2023; funding into 2025.
- New vectorized anti-Aβ antibody gene therapy research initiative for Alzheimer's disease launched.
- Executed license agreement with Sangamo for prion disease treatment using TRACER capsid.
- VY-TAU01 anti-tau antibody IND on track for H1 2024; GLP tox studies to start in 2023.

## SEC filing metadata
- accession: 0001558370-23-013047
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/vygr-20230803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013047
- JSON: https://secwatch.observer/filing/0001558370-23-013047.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013047.txt

## Key facts
- Earnings Releases
  Voyager Therapeutics, Inc. reported the six months ended June 30, 2023 results: revenue $155.3 million, net income Net income was $101.8 million.
  - Period: the six months ended June 30, 2023
  - Revenue: $155.3 million
  - Net income: Net income was $101.8 million
  - Result: reported results
  source text: Voyager had collaboration revenue of $155.3 million for the six months ended June 30, 2023 period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm
- Earnings Releases
  Voyager Therapeutics, Inc. reported the second quarter of 2023 results: revenue $4.9 million, net income Net loss was $22.2 million.
  - Period: the second quarter of 2023
  - Revenue: $4.9 million
  - Net income: Net loss was $22.2 million
  - Result: reported results
  source text: Voyager had collaboration revenue of $4.9 million for the second quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000155837023013047/0001558370-23-013047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.